## RMD: ResMed Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.2% below STRENGTH zone (4.0-10.0%); PEG 1.58 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($239.00)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Resmed CFO Sandercock sells $244,160 in stock**
- Source: Investing.com | 20251202T162900 | Somewhat-Bullish | Relevance: 100%
- Resmed CFO Brett Sandercock sold 1,000 shares of RMD stock for $244,160 on December 1, 2025, through a Rule 10b5-1 plan. Despite the sale, the stock has risen, and InvestingPro analysis suggests ResMed is undervalued with "GREAT" financial health. The company also reported strong Q4 2025 revenue of $1.35 billion, surpassing analyst forecasts.

**2. 1,187,798 Shares in ResMed Inc. $RMD Acquired by Norges Bank**
- Source: MarketBeat | 20251202T113256 | Somewhat-Bullish | Relevance: 100%
- Norges Bank acquired a significant new stake of 1,187,798 shares in ResMed Inc. (NYSE:RMD) during Q2, valued at approximately $306.45 million. This acquisition represents about 0.81% of the company, highlighting institutional confidence in the medical equipment provider. ResMed recently reported strong Q3 earnings, exceeding revenue and EPS estimates, and has a consensus "Moderate Buy" rating from analysts.

**3. ResMed Inc. Reports Changes in Beneficial Ownership**
- Source: MSN | 20251202T071041 | Somewhat-Bullish | Relevance: 100%
- The article reports changes in beneficial ownership for ResMed Inc., specifically detailing recent insider transactions. It highlights the acquisition of shares by Director John Joseph Lyons and presents the total holdings of various insider types, including officers, directors, and the top 10 shareholders.

**4. Should Goldmanâ€™s Conviction List Exit and New Stock Plans Require Action From ResMed (RMD) Investors?**
- Source: Sahm | 20251203T220820 | Neutral | Relevance: 100%
- ResMed (RMD) recently experienced a board member resignation, filed two large employee stock ownership-related registrations, and was removed from Goldman Sachs's APAC Conviction List. These events combine routine corporate actions with a significant institutional reassessment, potentially influencing investor perspective on ResMed's future. The article discusses how these changes interact with ResMed's investment narrative, particularly regarding long-term demand for sleep and respiratory care, market defense, and potential reimbursement pressures.

**5. ResMed Inc Reports Changes in CHESS Depositary Interests and Securities**
- Source: MSN | 20251203T173726 | Neutral | Relevance: 100%
- ResMed Inc. reported a change in its CHESS Depositary Interests (CDI) with a decrease of 3,189,451 CDIs, affecting 3,189,451 securities. This change became effective today, January 10, 2024.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-03 | Baird | $300 | $320 | -6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-03 | Baird | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 16 ($9.01M) |
| Sells | 17 ($5.01M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 13.1% (+1.6%)
- Blackrock Inc.: 8.4% (-1.3%)
- State Street Corpora: 4.5% (-1.0%)
- Bank Of New York Mel: 3.1% (-9.8%)
- Geode Capital Manage: 2.9% (+0.9%)

### Key Risks

1. Insider selling cluster: $5.0M in recent transactions.
2. Elevated short interest (8.3%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.58 elevated, pricing in significant growth expectations. Forward P/E 20.9x stretched relative to 10% growth. Quality metrics strong (ROE 25%, ROA 14%, margin 27%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.36). Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $35.7B |
| Beta | 0.87 |
| 52W Range | $199.92 - $293.81 |
| Short Interest | 8.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.58 |
| Forward P/E | 20.9 |
| Current P/E | 23.1 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.8% to -1.2% (-2.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.2pp (needs >4.0% for momentum thesis). Below SMA200 (1.00x), long-term trend not supportive. MACD histogram positive (1.14), confirming momentum. RSI neutral at 47. OFD pattern: -DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.17% (CS: 40) | Neutral |
| RSI_14 | 47.2 | Neutral |
| MACD Histogram | 1.14 | Bullish |
| vs SMA20 | 1.006x | Above |
| vs SMA50 | 0.965x | Below |
| vs SMA200 | 0.996x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $251.44
- **Stop Loss:** $239.00 (4.9% risk)
- **Target:** $263.88 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 76
- **Position Value:** $19,109.44
- **Portfolio %:** 19.11%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-05 (Est: $2.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.55 | +2.0% |
| 2025Q2 | $2.48 | $2.55 | +2.8% |
| 2025Q1 | $2.36 | $2.37 | +0.4% |
| 2024Q4 | $2.31 | $2.43 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*